Bcr-Abl 抑制抗癌药物伊马替尼、尼洛替尼和达沙替尼的合成。
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
机构信息
Innovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
出版信息
Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18.
PMID:23247657
Abstract
Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).
摘要
伊马替尼（1）、尼洛替尼（2）和达沙替尼（3）是批准用于治疗慢性髓性白血病（CML）的 Bcr-Abl 酪氨酸激酶抑制剂。本综述从期刊和专利文献中收集信息，提供了一个全面的参考来源，用于制备上述活性药物成分（API）的不同合成方法。
Zotero 插件